Release Details

The Chemours Company Reports Third Quarter 2016 Results; Significant Earnings and Margins Increases Driven by Progress on Transformation Plan and Improved Market Conditions

November 6, 2016

WILMINGTON, Del.Nov. 6, 2016 /PRNewswire/ --

Third Quarter 2016 Highlights

  • Net Sales of $1.4 billion
  • Net Income of $204 million, or $1.11 per diluted share, including gain on asset sales of $169 million, impairment charges of $46 million, interest expense of $51 million and restructuring costs of $14 million
  • Adjusted EBITDA of $268 million
  • Adjusted Net Income of $112 million, or $0.61 per diluted share

Other Highlights

  • Continued progress on all transformation plan objectives, including cost reductions, growth initiatives and portfolio rationalization
  • Improved cash from operating activities by ~$440 million year-to-date
  • Retired $315 million of long term debt through October 31, 2016
  • Generated ~$685 million in gross proceeds from Chemical Solutions divestitures
  • Increased full-year Adjusted EBITDA outlook to be between $740 and $775 million based on a net income range of approximately $265 to $290 million

The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, today announced financial results for the third quarter 2016.

Chemours President and CEO Mark Vergnano said, "We continue to make excellent progress on all aspects of our transformation plan, realizing an incremental $60 million of cost savings during the quarter. We are benefiting from the OpteonTM refrigerant ramp up and the expansion of our low-cost TiO2 capacity at Altamira, while at the same time, delivering our planned cost reductions." He continued, "We successfully completed the Chemical Solutions portfolio review during the quarter, generating substantial proceeds. And, in the quarter, our Titanium Technologies business benefited from more favorable market conditions, while the fluoropolymers market remained challenged. Transformation initiatives are pervasive throughout the company and our results speak for themselves."

Third quarter net sales were $1.4 billion, a decrease of 6 percent from $1.5 billion in the prior-year quarter, primarily due to the impact of divestitures. Third quarter net income was $204 million, or $1.11 per diluted share, versus net loss of $29 million, or ($0.16) per diluted share in the prior-year quarter. Adjusted EBITDA for the third quarter was $268 million versus $169 million in the prior-year quarter. Benefits from cost reductions, improved average prices in Titanium Technologies and improved profitability in Fluoroproducts was partially offset by the loss of Adjusted EBITDA from the asset sales within Chemical Solutions.

Sequentially, sales increased 1 percent to $1.4 billion in the third quarter. Third quarter net income was $222 million higher, or $1.21 per diluted share, versus the second quarter net loss of $18 million or ($0.10) per diluted share. The sales improvement was largely driven by higher seasonal volumes in Titanium Technologies and Fluoroproducts supplemented by higher TiO2 pricing. Third quarter Adjusted EBITDA increased $81 million from $187 million in the second quarter of 2016. Improved pricing in Titanium Technologies and OpteonTM refrigerant growth in Fluoroproducts were the primary drivers of the improved sequential performance, which were partially offset by unfavorable Corporate and Other expenses.

Titanium Technologies
In the third quarter, Titanium Technologies segment sales were $625 million, a 1 percent increase versus the prior-year quarter. Improved year-over-year global average TiO2 pricing increased sales 2 percent which was partially offset by minimal currency headwinds. Year-over-year, TiO2 volume was higher in all regions outside of China. Segment Adjusted EBITDA was $144 million, an 80 percent increase over the prior-year quarter. The increase in Adjusted EBITDA was primarily due to the benefits of price increases, transformation plan cost savings, and operational efficiencies.

Sequentially, versus the second quarter of 2016, sales increased 5 percent and Adjusted EBITDA increased $33 million, or 30 percent. The increase in sales was due to slightly stronger volumes and a higher global average price increase of approximately 3 percent. A volume increase of 2 percent was the result of stronger demand primarily in Asia and Latin America. Higher Adjusted EBITDA was driven by the benefits of global average price increases, stronger volumes and better utilization resulting in lower costs.

Fluoroproducts
Fluoroproducts segment sales in the third quarter were $591 million, an increase of 3 percent versus the prior-year quarter. A substantial increase in demand for Opteon™ refrigerants was mostly offset by government-imposed volume reductions of base refrigerants as well as competitive pricing pressure within fluoropolymers. Segment Adjusted EBITDA was $143 million, a 57 percent improvement versus the prior-year quarter. Increased contributions from Opteon™ refrigerants and transformation cost reductions were partially offset by unfavorable pricing and mix within our fluoropolymers product lines.

Sequentially, versus the second quarter of 2016, sales and Adjusted EBITDA increased 3 percent and 36 percent, respectively. The Opteon™ refrigerants ramp up and strong demand for certain fluoropolymers products more than offset regulatory-driven lower demand in base refrigerant sales. In addition to Opteon™ refrigerant growth, the increase in Adjusted EBITDA was primarily attributed to cost reductions.

Chemical Solutions
In the third quarter, Chemical Solutions segment sales were $182 million, a 38 percent decline versus the prior-year quarter.  Lower sales were driven by the divestitures of the Clean and Disinfect business, Sulfur Products and Beaumont Aniline facility, as well as reduced average prices based on contractual pass-through terms. Segment Adjusted EBITDA was $9 million$1 million above the prior-year quarter, reflecting lower operating costs partially offset by the impacts of the divestitures.

Sequentially, sales decreased 15 percent versus the second quarter of 2016, while Adjusted EBITDA was $2 million lower driven primarily by portfolio changes completed in the current quarter.

In the third quarter, we completed the sales of Sulfur Products and the Clean and Disinfect business to Veolia and LANXESS, respectively, for combined proceeds of approximately $544 million. Also, consistent with the company's plan to streamline the portfolio and deliver cost savings in 2017, the company ceased production at the Niagara Reactive Metals facility at the end of September.

Corporate and Other
Corporate and Other represented a negative $28 million of Adjusted EBITDA, an increase of $18 million versus the prior-year quarter. Higher expenses were primarily related to performance-related compensation adjustments and other miscellaneous expenses in the quarter. Versus the second quarter of 2016, Corporate and Other expenses declined $12 million largely due to timing of expenses.

The company realized a cash tax rate of approximately 16 percent in the quarter. For the full year 2016, the company expects its cash tax rate to be in the low-twenties on a percentage basis, taking into consideration the company's anticipated geographic mix of earnings and implications of all divestitures during the year.

Liquidity
As of September 30, 2016, gross consolidated debt was $3.8 billion. Debt, net of cash, was $2.8 billion. In the quarter, the company retired approximately $115 million of its bonds. Cash balances were $957 million at September 30, 2016. In October 2016, the company retired an additional $107 million of its bonds, resulting in over $315 million of total long term debt retired year-to-date. As a result, the company expects to save approximately $19 million annually from lower interest obligations.

Improved inventory management along with the start of seasonal working capital unwind drove strong progress in working capital results and led to free cash flow of $132 million, up $124 million versus the previous-year quarter.  Year-to-date working capital1 performance and free cash flow improved by $448 million and $601 million, respectively, versus the prior-year.

Outlook
"We remain disciplined and focused on executing our Five-Point Transformation Plan," Vergnano commented. "We expect the transformation plan improvements, along with a stronger price environment for TiO2 and increased OpteonTM refrigerants adoption to continue to enhance earnings, despite loss of earnings from divestitures, base refrigerant sales timing and unfavorable Fluoropolymers mix. We now expect full-year 2016 Adjusted EBITDA to be between $740 million and $775 million. We are pleased with the progress we have made year-to-date, and believe we are in a stronger position as we move forward."

Conference Call
As previously announced, Chemours will hold a conference call and webcast on Monday, November 7, 2016 at 8:30 AM EST. The webcast and additional presentation materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on the Chemours' investor website.

About The Chemours Company
The Chemours Company (NYSE: CC) helps create a colorful, capable and cleaner world through the power of chemistry.  Chemours is a global leader in titanium technologies, fluoroproducts and chemical solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations.  Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining and oil refining operations and general industrial manufacturing.  Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™ and Nafion™.  Chemours has approximately 8,000 employees across 25 manufacturing sites serving more than 5,000 customers in North America, Latin AmericaAsia-Pacific and Europe.  Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.  For more information please visit chemours.com.

Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted Accounting Principles ("GAAP"). Within this press release, we make reference to Adjusted Net Income (Loss), Adjusted Diluted Income (Loss) per share and Adjusted EBITDA and Free Cash Flow, which are non-GAAP financial measures. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making.

Management uses Adjusted Net Income (Loss), Adjusted Diluted Income (Loss) per share, Adjusted EBITDA and Free Cash Flow to evaluate the company's performance excluding the impact of certain non-cash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Accordingly, the company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the company's financial statements and footnotes contained in the documents that the company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the company in this press release may be different from the methods used by other companies. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of Non-GAAP Financial Measures to GAAP Financial Measures" and materials posted to the website at investors.chemours.com.

Forward-Looking Statements
This press release contains forward-looking statements, which often may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements also are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements, as further described in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended December 31, 2015Chemours undertakes no duty to update any forward-looking statements.

CONTACT:

MEDIA:
Alvenia Scarborough
Director, Brand Marketing and Corporate Communications
+1.302.773.4507
alvenia.g.scarborough@chemours.com 

INVESTORS:
Alisha Bellezza
Treasurer and Director of Investor Relations
+1.302.773.2263
investor@chemours.com

 

The Chemours Company 
Consolidated Statements of Operations (Unaudited) 
(Dollars in millions, except per share amounts)

 
 

Three months ended

 

Nine months ended

 

September 30,

 

September 30,

 

2016

 

2015

 

2016

 

2015

Net sales

$

1,398

  

$

1,486

  

$

4,078

  

$

4,357

 

Cost of goods sold

1,056

  

1,222

  

3,267

  

3,615

 

Gross profit

342

  

264

  

811

  

742

 

Selling, general and administrative expense

148

  

157

  

454

  

481

 

Research and development expense

19

  

18

  

60

  

68

 

Restructuring and asset related charges, net

60

  

184

  

145

  

245

 

Goodwill impairment

  

25

  

  

25

 

Total expenses

227

  

384

  

659

  

819

 

Equity in earnings of affiliates

9

  

7

  

17

  

18

 

Interest expense, net

(51)

  

(51)

  

(157)

  

(79)

 

Other income, net

161

  

57

  

250

  

71

 

Income (loss) before income taxes

234

  

(107)

  

262

  

(67)

 

Provision (benefit from) for income taxes

30

  

(78)

  

25

  

(63)

 

Net income (loss)

204

  

(29)

  

237

  

(4)

 

Less: Net income attributable to noncontrolling interests

  

  

  

 

Net income (loss) attributable to Chemours

$

204

  

$

(29)

  

$

237

  

$

(4)

 
        

Per share data

       

Basic earnings (loss) per share of common stock

$

1.12

  

$

(0.16)

  

$

1.31

  

$

(0.02)

 

Diluted earnings per share of common stock

$

1.11

  

$

(0.16)

  

$

1.30

  

$

(0.02)

 

Dividends per share of common stock

$

0.03

  

$

0.03

  

$

0.09

  

$

0.58

 

 

 

The Chemours Company 
Consolidated Balance Sheets 
(Dollars in millions, except per share amounts)

 
 

September 30,
 2016

 

December 31,
 2015

 

(Unaudited)

  

Assets

   

Current assets:

   

Cash and cash equivalents

$

957

  

$

366

 

Accounts and notes receivable - trade, net

881

  

859

 

Inventories

846

  

972

 

Prepaid expenses and other

73

  

104

 

Total current assets

2,757

  

2,301

 

Property, plant and equipment

8,218

  

9,015

 

Less: Accumulated depreciation

(5,393)

  

(5,838)

 

Net property, plant and equipment

2,825

  

3,177

 

Goodwill

153

  

166

 

Other intangible assets, net

18

  

10

 

Investments in affiliates

169

  

136

 

Other assets

367

  

508

 

Total assets

$

6,289

  

$

6,298

 

Liabilities and equity

   

Current liabilities:

   

Accounts payable

$

835

  

$

973

 

Short-term borrowings and current maturities of long-term debt

32

  

39

 

Other accrued liabilities

569

  

454

 

Total current liabilities

1,436

  

1,466

 

Long-term debt, net

3,713

  

3,915

 

Deferred income taxes

201

  

234

 

Other liabilities

558

  

553

 

Total liabilities

5,908

  

6,168

 

Commitments and contingent liabilities

   

Equity

   

Common stock (par value $0.01 per share; 810,000,000 shares authorized; 181,720,722 shares issued and outstanding as of September 30, 2016)

2

  

2

 

Additional paid in capital

781

  

775

 

Retained earnings (accumulated deficit)

117

  

(115)

 

Accumulated other comprehensive loss

(523)

  

(536)

 

Total Chemours stockholders' equity

377

  

126

 

Noncontrolling interests

4

  

4

 

Total equity

381

  

130

 

Total liabilities and equity

$

6,289

  

$

6,298

 

 

 

The Chemours Company 
Consolidated Statements of Cash Flows (Unaudited) 
(Dollars in millions)

 
 

Nine months ended

 

September 30,

 

2016

 

2015

Operating activities

   

Net income (loss)

$

237

  

$

(4)

 

Adjustments to reconcile net income (loss) to cash used for operating activities:

   

Depreciation and amortization

212

  

201

 

Amortization of debt issuance costs and discount

15

  

5

 

Gain on sale of assets and business

(258)

  

 

Equity in earnings of affiliates

(17)

  

(18)

 

Deferred tax benefits

(29)

  

(86)

 

Asset related charges

109

  

191

 

Other operating charges and credits, net

33

  

17

 

(Increase) decrease in operating assets:

   

     Accounts and notes receivable - trade, net

(63)

  

(250)

 

     Inventories and other operating assets

113

  

(29)

 

Decrease in operating liabilities:

   

     Accounts payable and other operating liabilities

(28)

  

(147)

 

Cash provided by (used for) operating activities

324

  

(120)

 

Investing activities

   

Purchases of property, plant and equipment

(235)

  

(392)

 

 Purchase of Intangible Assets

   

Proceeds from sales of assets and business, net of cash transferred

707

  

8

 

Foreign exchange contract settlements

(1)

  

61

 

Investment in affiliates

(2)

  

(32)

 

Cash provided by (used for) investing activities

469

  

(355)

 

Financing activities

   

Proceeds from issuance of debt, net

  

3,490

 

Debt repayments

(212)

  

(6)

 

Deferred financing fees

(2)

  

(79)

 

Dividends paid

(16)

  

(100)

 

Cash provided at separation by DuPont

  

247

 

Net transfers to DuPont

  

(2,857)

 

Cash (used for) provided by financing activities

(230)

  

695

 

Effect of exchange rate changes on cash and cash equivalents

28

  

(5)

 

Increase in cash and cash equivalents

591

  

215

 

Cash and cash equivalents at beginning of period

366

  

 

Cash and cash equivalents at end of period

$

957

  

$

215

 
    

Non-cash investing activities:

   

Change in property, plant and equipment included in accounts payable

$

9

  

$

(42)

 

 

 

 

The Chemours Company 
Segment Financial and Operating Data (Unaudited) 
(Dollars in millions)

 

Segment Net Sales

Three months ended

  

Three months ended

Sequential

 

September 30,

Increase / 
(Decrease)

 

June 30,

Increase / 
(Decrease)

 

2016

2015

 

2016

Titanium Technologies

$

625

 

$

616

 

$

9

  

$

596

 

$

29

 

Fluoroproducts

591

 

575

 

16

  

573

 

18

 

Chemical Solutions

182

 

295

 

(113)

  

214

 

(32)

 

Net sales

$

1,398

 

$

1,486

 

$

(88)

  

$

1,383

 

$

15

 
      

Segment Adjusted EBITDA

Three months ended

  

Three months ended

Sequential

 

September 30,

Increase / 
(Decrease)

 

June 30,

Increase / 
(Decrease)

 

2016

2015

 

2016

Titanium Technologies

$

144

 

$

80

 

$

64

  

$

111

 

$

33

 

Fluoroproducts

143

 

91

 

52

  

105

 

38

 

Chemical Solutions

9

 

8

 

1

  

11

 

(2)

 

Corporate and Other

(28)

 

(10)

 

(18)

  

(40)

 

12

 

Total Adjusted EBITDA

$

268

 

$

169

 

$

99

  

$

187

 

$

81

 
       

Adjusted EBITDA Margin

19

%

11

%

  

14

%

 

 

 

Quarterly Change in Net Sales from September 30, 2015

  
 

September 30, 
2016

Net Sales

Percentage 
Change vs 
2015

Percentage change due to:

 

Local Price

Volume

Currency 
Effect

Portfolio / 
Other

Total Company

$

1,398

 

(6)%

(1)%

—%

—%

(5)%

       

Titanium Technologies

$

625

 

1%

1%

—%

—%

—%

Fluoroproducts

$

591

 

3%

(2)%

5%

—%

—%

Chemical Solutions

$

182

 

(38)%

(7)%

(5)%

—%

(26)%

   

Quarterly Change in Net Sales from June 30, 2016

  
 

September 30, 
2016

Net Sales

Percentage 
Change vs 
June 30, 2016

Percentage change due to:

 

Local Price

Volume

Currency 
Effect

Portfolio / 
Other

Total Company

$

1,398

 

1%

1%

3%

—%

(3)%

       

Titanium Technologies

$

625

 

5%

3%

2%

—%

—%

Fluoroproducts

$

591

 

3%

—%

3%

—%

—%

Chemical Solutions

$

182

 

(15)%

(3)%

9%

—%

(21)%

 

 

The Chemours Company 
Segment Financial and Operating Data (Unaudited) 
(Dollars in millions)

 

Segment Net Sales

Nine months ended

 
 

September 30,

Increase / 
(Decrease)

 

2016

2015

Titanium Technologies

$

1,742

 

$

1,803

 

$

(61)

 

Fluoroproducts

1,695

 

1,715

 

(20)

 

Chemical Solutions

641

 

839

 

(198)

 

Net sales

$

4,078

 

$

4,357

 

$

(279)

 
   

Segment Adjusted EBITDA

Nine months ended

 
 

September 30,

Increase / 
(Decrease)

 

2016

2015

Titanium Technologies

$

309

 

$

264

 

$

45

 

Fluoroproducts

333

 

220

 

113

 

Chemical Solutions

30

 

13

 

17

 

Corporate and Other

(89)

 

(56)

 

(33)

 

Total Adjusted EBITDA

$

583

 

$

441

 

$

142

 
    

Adjusted EBITDA Margin

14

%

10

%

 

 

 

Year-to-date Change in Net Sales from September 30, 2015

  
 

2016

Net Sales

Percentage 
Change vs 
2015

Percentage change due to:

 

Local Price

Volume

Currency 
Effect

Portfolio / 
Other

Total Company

$

4,078

 

(6)%

(4)%

1%

(1)%

(2)%

       

Titanium Technologies

$

1,742

 

(3)%

(6)%

3%

—%

—%

Fluoroproducts

$

1,695

 

(1)%

—%

1%

(2)%

—%

Chemical Solutions

$

641

 

(24)%

(8)%

(4)%

—%

(12)%

 

 

The Chemours Company 
Reconciliations of Non-GAAP Information (Unaudited)

 

GAAP Net Income (Loss) to Adjusted Net Income and Adjusted EBITDA Tabular Reconciliations 
(Dollars in millions)

 
  

Three months ended

 

Nine months ended

  

September 30,

 

June 30,

 

September 30,

  

2016

 

2015

 

2016

 

2016

 

2015

Net income (loss) attributable to Chemours

 

$

204

  

$

(29)

  

$

(18)

  

$

237

  

$

(4)

 

Non-operating pension and other postretirement employee benefit (income) costs

 

(5)

  

(10)

  

(7)

  

(19)

  

5

 

Exchange losses (gains)

 

17

  

(44)

  

14

  

37

  

(47)

 

Restructuring charges

 

14

  

139

  

9

  

41

  

200

 

Asset related charges1

 

46

  

70

  

63

  

109

  

70

 

(Gain) loss on sale of assets or business

 

(169)

  

  

1

  

(258)

  

 

Transaction costs2

 

2

  

  

12

  

18

  

 

Legal and other charges3

 

5

  

  

13

  

24

  

 

(Benefit from) provision for income taxes relating to reconciling items4

 

(2)

  

(53)

  

(38)

  

(16)

  

(82)

 

Adjusted Net Income

 

112

  

73

  

49

  

173

  

142

 

Net income attributable to noncontrolling interests

 

  

  

  

  

 

Interest expense, net

 

51

  

51

  

50

  

157

  

79

 

Depreciation and amortization

 

73

  

70

  

73

  

212

  

201

 

All remaining provision for (benefit from) income taxes4

 

32

  

(25)

  

15

  

41

  

19

 

Adjusted EBITDA

 

$

268

  

$

169

  

$

187

  

$

583

  

$

441

 
           

 

  
  

1

The three and nine months ended September 30, 2016 includes $46 million pre-tax asset impairment of our Pascagoula Aniline facility and other asset write-offs.  The nine months ended September 30, 2016 also included $58 million pre-tax asset impairment in connection with the sale of the Sulfur business and other asset write-offs, which were recorded in the second quarter of 2016.  The three and nine months ended September 30, 2015 includes $25 million of goodwill impairment and $45 asset impairment of the RMS facility.  All of these charges are recorded in the Chemical Solutions segment.

2

Includes accounting, legal and bankers transaction fees incurred related to the Company's strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses.

3

Includes litigation settlements, water treatment accruals related to PFOA, and lease termination charges.

4

Total of provision for (benefit from) income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015.

 

Adjusted Net Income diluted earnings per share is calculated using Adjusted Net Income divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares.  The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share and adjusted earnings per share calculations for the periods indicated:

 

  

Three months ended

 

Nine months ended

  

September 30,

 

June 30,

 

September 30,

  

2016

 

2015

 

2016

 

2016

 

2015

Numerator:

          

Net income

 

$

204

  

$

(29)

  

$

(18)

  

$

237

  

$

(4)

 

Adjusted Net Income

 

$

112

  

$

73

  

$

49

  

$

173

  

$

142

 

Denominator:

          

Weighted-average number of common shares outstanding - Basic

 

181,596,161

  

180,968,049

  

181,477,672

  

181,452,194

  

180,968,049

 

Dilutive effect of the company's employee compensation plans 5

 

1,932,395

  

918,680

  

1,114,845

  

1,089,738

  

918,680

 

Weighted average number of common shares outstanding - Diluted

 

183,528,556

  

181,886,729

  

182,592,517

  

182,541,932

  

181,886,729

 
           

Earnings per share - basic

 

$

1.12

  

$

(0.16)

  

$

(0.10)

  

$

1.31

  

$

(0.02)

 

Earnings per share - diluted5

 

$

1.11

  

$

(0.16)

  

$

(0.10)

  

$

1.30

  

$

(0.02)

 

Adjusted earnings per share – basic

 

$

0.62

  

$

0.40

  

$

0.27

  

$

0.95

  

$

0.78

 

Adjusted earnings per share - diluted5

 

$

0.61

  

$

0.40

  

$

0.27

  

$

0.95

  

$

0.78

 
  
  

5

Diluted earnings (loss) per share is calculated using net income (loss) available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect.

 

 

The Chemours Company 
Reconciliations of Non-GAAP Information (Unaudited)

 

Estimated Income Before Income Taxes and Estimated Adjusted EBITDA Tabular Reconciliations 
(Dollars in millions)

 
 

2016 Full Year Estimate

(Dollars in millions)

Low

 

High

Net income attributable to Chemours

$

265

  

$

290

 

Non-operating pension and other postretirement employee benefit (income) costs

(25)

  

(20)

 

Exchange losses1

37

  

37

 

Restructuring charges

50

  

45

 

Asset related charges2

109

  

109

 

Gain on sale of assets or business2

(258)

  

(258)

 

Transaction costs, legal and other charges2

42

  

42

 

Provision for income taxes relating to reconciling items3

(20)

  

(20)

 

Adjusted pre-tax income

200

  

225

 

Net income attributable to noncontrolling interests

  

 

Interest expense, net

210

  

210

 

Depreciation and amortization

280

  

280

 

All remaining provision for income taxes3

50

  

60

 

Adjusted EBITDA

$

740

  

$

775

 
  
  

1

The amount represents the year-to-date net exchange losses incurred in the nine months ended September 30, 2016.  Full year actual results could differ from the current estimate. and therefore could also change our estimated income before income taxes.  Forecasting the remeasurement impact of foreign currency exchange fluctuation is not practical without unreasonable effort.

2

At this time, we cannot estimate additional impairment, gain on sale, transaction costs and legal and other charges.  Therefore, the amounts included are the same as the actual amounts reported in the nine months period ended September 30, 2016.

3

Provision for (benefit from) income taxes were estimated based upon current geographical mix of earnings.  Actual provision for (benefit from) income tax could defer from current estimate.

 

 

GAAP Cash Flow to Free Cash Flow Tabular Reconciliations

 
  

Three months ended

 

Nine months ended

  

September 30,

 

June 30,

 

September 30,

  

2016

 

2015

 

2016

 

2016

 

2015

Cash flow provided by (used for) operating activities

 

$

199

  

$

113

  

$

90

  

$

324

  

$

(120)

 

Cash flow used for purchases of property, plant and 
equipment

 

(67)

  

(105)

  

(79)

  

(235)

  

(392)

 

Free cash flows 4

 

$

132

  

$

8

  

$

11

  

$

89

  

$

(512)

 
  
  

4

Cash flows from operating activities for the nine months ended September 30, 2016 include the DuPont prepayments outstanding balance of approximately $93 million.  Excluding the DuPont prepayment, free cash flows for the nine months ended September 30, 2016 would have been negative $4 million.

 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-chemours-company-reports-third-quarter-2016-results-significant-earnings-and-margins-increases-driven-by-progress-on-transformation-plan-and-improved-market-conditions-300358103.html

SOURCE The Chemours Company